GO Therapeutics CSO review on site-specific O-glycans in human tissue formation, O-glycan occupancy, and contributions from individual GalNAc-Ts
Professor Hans Wandall review published in Nature
Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin
GO Therapeutics Scientific Co-Founder & Chief Scientific Officer Hans Wandall, M.D., Ph.D. co-authors article published in British Journal of Cancer.